HEALTH TECHNOLOGY ASSESSMENT REPORT FOR POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH CANCER

Author(s)

Alcaraz A*1;Meza V2;Glujovsky D3;Romano M2;Morelli D2;Comandé D3;Garcia Marti S2;Pichon Riviere A4, Augustovski F5 1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Institute for Clinical Effectiveness and Health Po

OBJECTIVES: Positron Emission Tomography (PET) might be useful for cancer staging and follow-up. The objetive was to assess the available evidence on efficacy, safety and coverage policies for use of PET in oncology. METHODS: A bibliographic search was carried in PubMed, DARE, NHS EED, in health technology assessment (HTA) agencies and health insurers. Priority was given to systematic reviews; randomized clinical trials (RCTs); HTA; clinical practice guidelines (CPGs) and coverage policies (CPs). RESULTS: Thirty seven systematic reviews, 3 RCTs and 32 observational studies, 51 CPGs, 15 HTAs and 28 CPs were included. Breast Cancer (17 studies):There is no evidence of its use as routine practice. Some CPGs and CPs recommend it for suspicious images that could not be clarified through conventional studies. PET is not recommended for axillary staging or neodadyuvant response prediction. Lung Cancer (44 studies):The accuracy for lung nodule is similar to conventional methods. Most CPGs do not recommend the use of PET for lung cancer staging except in some non-small cell lung cancer with previous negative tests for metastasis. Colorectal Cancer (20 studies): There is no evidence of its use as routine practice. It might be used in patients with suspected recurrence and non-conclusive images. Genitourinary Tumors (70 studies): PET might be associated with changes in diagnosis or therapeutic only in specific cases, such as ovarian cancer with suspected recurrence and normal conventional images, in residual tumors due to seminoma and cervical cancer recurrence eligible for curative treatment. Primary Tumors of the Central Nervous System (15 studies):PET is not recommended as routine practice. CPGs, RCTs and CPs recognize its usefulness for differential diagnosis between relapse and radionecrosis. CONCLUSIONS: There is no evidence to support the use of PET in cancer patients as routine practice. At present, its use should be restricted to specific patients.

Conference/Value in Health Info

2013-09, ISPOR Latin America 2013, Buenos Aires, Argentina

Value in Health, Vol. 16, No. 7 (November 2013)

Code

HT2

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes

Disease

Multiple Diseases, Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×